Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2010 2
2011 3
2012 1
2013 3
2014 1
2015 1
2016 2
2018 3
2019 4
2020 2
2021 2
2022 5
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies.
Ieranò C, Righelli D, D'Alterio C, Napolitano M, Portella L, Rea G, Auletta F, Santagata S, Trotta AM, Guardascione G, Liotti F, Prevete N, Maiolino P, Luciano A, Barbieri A, Di Mauro A, Roma C, Esposito Abate R, Tatangelo F, Pacelli R, Normanno N, Melillo RM, Scala S. Ieranò C, et al. Among authors: roma c. J Immunother Cancer. 2022 Mar;10(3):e004032. doi: 10.1136/jitc-2021-004032. J Immunother Cancer. 2022. PMID: 35246475 Free PMC article.
The role of circulating free DNA in the management of NSCLC.
Esposito Abate R, Pasquale R, Fenizia F, Rachiglio AM, Roma C, Bergantino F, Forgione L, Lambiase M, Sacco A, Piccirillo MC, Morabito A, Normanno N. Esposito Abate R, et al. Among authors: roma c. Expert Rev Anticancer Ther. 2019 Jan;19(1):19-28. doi: 10.1080/14737140.2019.1548938. Epub 2018 Nov 29. Expert Rev Anticancer Ther. 2019. PMID: 30462523 Review.
GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles.
Pozzorini C, Andre G, Coletta T, Buisson A, Bieler J, Ferrer L, Kempfer R, Saintigny P, Harlé A, Vacirca D, Barberis M, Gilson P, Roma C, Saitta A, Smith E, Consales Barras F, Ripol L, Fritzsche M, Marques AC, Alkodsi A, Marin R, Normanno N, Grimm C, Müllauer L, Harter P, Pignata S, Gonzalez-Martin A, Denison U, Fujiwara K, Vergote I, Colombo N, Willig A, Pujade-Lauraine E, Just PA, Ray-Coquard I, Xu Z. Pozzorini C, et al. Among authors: roma c. Cell Rep Med. 2023 Dec 19;4(12):101344. doi: 10.1016/j.xcrm.2023.101344. Cell Rep Med. 2023. PMID: 38118421 Free PMC article.
Challenges in bioinformatics approaches to tumor mutation burden analysis.
Fenizia F, Pasquale R, Abate RE, Lambiase M, Roma C, Bergantino F, Chaudhury R, Hyland F, Allen C, Normanno N. Fenizia F, et al. Among authors: roma c. Oncol Lett. 2021 Jul;22(1):555. doi: 10.3892/ol.2021.12816. Epub 2021 May 24. Oncol Lett. 2021. PMID: 34084222 Free PMC article.
Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies.
Rachiglio AM, Forgione L, Pasquale R, Barone CA, Maiello E, Antonuzzo L, Cassata A, Tonini G, Bordonaro R, Rosati G, Zaniboni A, Lonardi S, Ferrari D, Frassineti GL, Tamberi S, Pisconti S, Di Fabio F, Roma C, Orlandi A, Latiano T, Damato A, Tortora G, Pinto C, Normanno N. Rachiglio AM, et al. Among authors: roma c. Cancers (Basel). 2022 Feb 18;14(4):1052. doi: 10.3390/cancers14041052. Cancers (Basel). 2022. PMID: 35205799 Free PMC article.
Study of Ras Mutations' Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis.
Ottaiano A, Normanno N, Facchini S, Cassata A, Nappi A, Romano C, Silvestro L, De Stefano A, Rachiglio AM, Roma C, Maiello MR, Scala S, Delrio P, Tatangelo F, Di Mauro A, Botti G, Avallone A, Nasti G. Ottaiano A, et al. Among authors: roma c. Cancers (Basel). 2020 Jul 16;12(7):1919. doi: 10.3390/cancers12071919. Cancers (Basel). 2020. PMID: 32708575 Free PMC article.
30 results